{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:41:16Z","timestamp":1786372876042,"version":"build-2736575974"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Coronary heart disease (CHD) is the leading cause of death in Western civilizations, in particular in chronic kidney disease (CKD) patients. Serum total cholesterol and LDL have been linked to the development of atherosclerosis and progression to CHD in the general population. However, the reductions of total and LDL cholesterol in the dialysis population have not demonstrated the ability to reduce the morbidity, mortality, and cost burden associated with CHD. The patients at greatest risk include those with pre-existing CHD, a CHD-risk equivalent, or multiple risk factors. However, data in the dialysis population are much less impressive, and the relationship between plasma cholesterol, cholesterol reduction, use of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, and reduction in incidence of CHD or effect on progression of renal disease have not been proven. Adverse event information from published trials indicates that agents within this class share similar tolerability and adverse event profiles. Hepatic transaminase elevations may occur in 1 to 2% of patients and is dose related. Myalgia, myopathy, and rhabodmyolysis occur infrequently and are more common in kidney transplant patients and patients with CKD. This effect appears to be dose related and may be precipitated by administration with agents that inhibit cytochrome P-450 isoenzymes. Caution should be exercised when coadministering any statin with drugs that metabolize through cytochrome P-450 IIIA-4 in particular fibrates, cyclosporine, and azole antifungals. Elderly patients with CKD are at greater risk of adverse drug reactions, and therefore the lowest possible dose of statins should be used for the treatment of hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.09091010","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T22:45:41Z","timestamp":1299797141000},"page":"664-678","source":"Crossref","is-referenced-by-count":21,"title":["The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients"],"prefix":"10.2215","volume":"6","author":[{"given":"Ali","family":"Olyaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Delos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20230811","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can J Cardiol"},{"key":"R2-28-20230811","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"R4-28-20230811","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.00780306","article-title":"Management of dyslipidemias in patients with diabetes and chronic kidney disease","volume":"1","author":"Molitch","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-28-20230811","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R7-28-20230811","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1185\/03007990802622064","article-title":"Cardiovascular disease in patients with renal disease: The role of statins","volume":"25","author":"Fellstrom","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R8-28-20230811","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1517\/14656566.6.8.1291","article-title":"Statin response and pharmacokinetics variants","volume":"6","author":"Kajinami","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"R9-28-20230811","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2215\/CJN.04320709","article-title":"Coronary calcification in patients with chronic kidney disease and coronary artery disease","volume":"4","author":"Nakamura","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-28-20230811","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R12-28-20230811","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: Focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"R13-28-20230811","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/dc09-0621","article-title":"Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: The FIELD Helsinki substudy","volume":"33","author":"Forsblom","year":"2010","journal-title":"Diabetes Care"},{"key":"R14-28-20230811","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R15-28-20230811","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"R16-28-20230811","first-page":"S24","article-title":"Epidemiology of cardiovascular risk factors in chronic renal disease","volume":"9","author":"Coresh","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R17-28-20230811","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"R18-28-20230811","first-page":"34","article-title":"Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney","volume":"79","author":"Tomilina","year":"2007","journal-title":"Ter Arkh"},{"key":"R19-28-20230811","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/01.RES.62.2.367","article-title":"Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5\/6 nephrectomy model of chronic renal failure","volume":"62","author":"Kasiske","year":"1988","journal-title":"Circ Res"},{"key":"R20-28-20230811","first-page":"433","article-title":"Induction of glomerulosclerosis by dietary lipids: A functional and morphologic study in the rat","volume":"60","author":"Grone","year":"1989","journal-title":"Lab Invest"},{"key":"R21-28-20230811","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1681\/ASN.2005010106","article-title":"Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults","volume":"16","author":"Kurella","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R22-28-20230811","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"R23-28-20230811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R24-28-20230811","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","article-title":"Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study","volume":"73","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"R25-28-20230811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2362.1990.tb01798.x","article-title":"The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy","volume":"20","author":"Rayner","year":"1990","journal-title":"Eur J Clin Invest"},{"key":"R26-28-20230811","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R27-28-20230811","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.0000022805.11288.7F","article-title":"Effect of pravastatin on proteinuria in patients with well-controlled hypertension","volume":"40","author":"Lee","year":"2002","journal-title":"Hypertension"},{"key":"R28-28-20230811","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/0091270006292629","article-title":"Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia","volume":"46","author":"Kostapanos","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R29-28-20230811","doi-asserted-by":"crossref","first-page":"82C","DOI":"10.1016\/j.amjcard.2005.12.015","article-title":"An assessment of statin safety by nephrologists","volume":"97","author":"Kasiske","year":"2006","journal-title":"Am J Cardiol"},{"key":"R30-28-20230811","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"R33-28-20230811","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/08860221003759452","article-title":"Acute renal failure with the combined use of rosuvastatin and fenofibrate","volume":"32","author":"Buyukhatipoglu","year":"2010","journal-title":"Ren Fail"},{"key":"R34-28-20230811","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1515\/DMDI.2009.24.1.83","article-title":"Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation","volume":"24","author":"Gallelli","year":"2009","journal-title":"Drug Metabol Drug Interact"},{"key":"R38-28-20230811","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"R39-28-20230811","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R40-28-20230811","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2215\/CJN.03380410","article-title":"Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: The ESPLANADE trial","volume":"5","author":"Ruggenenti","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R41-28-20230811","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2369-9-4","article-title":"The Lipid lowering and Onset of Renal Disease (LORD) trial: A randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease","volume":"9","author":"Fassett","year":"2008","journal-title":"BMC Nephrol"},{"key":"R42-28-20230811","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"R44-28-20230811","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/157016111793744742","article-title":"New concept of vascular calcification and metabolism","volume":"9","author":"Nakagami","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"R46-28-20230811","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00268-005-7531-8","article-title":"Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan","volume":"29","author":"Akioka","year":"2005","journal-title":"World J Surg"},{"key":"R47-28-20230811","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/08860220701460111","article-title":"Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients","volume":"29","author":"Kimak","year":"2007","journal-title":"Ren Fail"},{"key":"R48-28-20230811","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/00007890-199012000-00018","article-title":"The prevalence of hyperlipidemia in renal transplant recipients: Associations with immunosuppressive and antihypertensive therapy","volume":"50","author":"Bittar","year":"1990","journal-title":"Transplantation"},{"key":"R49-28-20230811","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0272-6386(12)80095-3","article-title":"Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia","volume":"18","author":"Hricik","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"R50-28-20230811","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0022-3565(24)39134-7","article-title":"Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions","volume":"294","author":"Vaziri","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R51-28-20230811","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.transproceed.2006.08.070","article-title":"Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: A prospective study","volume":"38","author":"Marc\u00e9n","year":"2006","journal-title":"Transplant Proc"},{"key":"R52-28-20230811","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/TP.0b013e318199c1c7","article-title":"Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation","volume":"87","author":"Opelz","year":"2009","journal-title":"Transplantation"},{"key":"R53-28-20230811","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"R54-28-20230811","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/00007890-200008150-00012","article-title":"Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection","volume":"70","author":"Wissing","year":"2000","journal-title":"Transplantation"},{"key":"R55-28-20230811","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.tp.0000235446.50715.ef","article-title":"Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation","volume":"82","author":"Wissing","year":"2006","journal-title":"Transplantation"},{"key":"R56-28-20230811","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"R57-28-20230811","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","author":"Furberg","year":"2002","journal-title":"JAMA"},{"key":"R58-28-20230811","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R59-28-20230811","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"R60-28-20230811","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT Study","volume":"4","author":"Jardine","year":"2004","journal-title":"Am J Transplant"},{"key":"R61-28-20230811","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-6143.2006.01263.x","article-title":"A retrospective analysis of ezetimibe treatment in renal transplant recipients","volume":"6","author":"Buchanan","year":"2006","journal-title":"Am J Transplant"},{"key":"R62-28-20230811","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ndt\/gfm620","article-title":"Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: A pilot study","volume":"23","author":"T\u00fcrk","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R63-28-20230811","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/01.tp.0000203167.77570.11","article-title":"Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors","volume":"81","author":"Langone","year":"2006","journal-title":"Transplantation"},{"key":"R64-28-20230811","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-6143.2005.01132.x","article-title":"Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation","volume":"6","author":"Kohnle","year":"2006","journal-title":"Am J Transplant"},{"key":"R65-28-20230811","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.atherosclerosis.2008.08.022","article-title":"The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis","volume":"203","author":"Blum","year":"2009","journal-title":"Atherosclerosis"},{"key":"R66-28-20230811","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/archinte.160.15.2273","article-title":"Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism-monograph for physicians","volume":"160","author":"Bottorff","year":"2000","journal-title":"Arch Intern Med"},{"key":"R67-28-20230811","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0735-1097(98)00300-3","article-title":"Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin","volume":"32","author":"Brown","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R68-28-20230811","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00003495-200161020-00005","article-title":"Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust","volume":"61","author":"Davidson","year":"2001","journal-title":"Drugs"},{"key":"R69-28-20230811","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf"},{"key":"R71-28-20230811","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ajg.2010.102","article-title":"The myth of statin-induced hepatotoxicity","volume":"105","author":"Bader","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R72-28-20230811","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pds.1603","article-title":"The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care","volume":"17","author":"Garc\u00eda-Rodr\u00edguez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R73-28-20230811","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"R75-28-20230811","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R76-28-20230811","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"R77-28-20230811","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"R78-28-20230811","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"R79-28-20230811","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R82-28-20230811","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"R83-28-20230811","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjcard.2010.03.033","article-title":"Comparison of atorvastatin 80 mg\/day versus simvastatin 20 to 40 mg\/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)","volume":"106","author":"Pedersen","year":"2010","journal-title":"Am J Cardiol"},{"key":"R84-28-20230811","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"R85-28-20230811","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R87-28-20230811","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1185\/03007990802622064","article-title":"Cardiovascular disease in patients with renal disease: The role of statins","volume":"25","author":"Fellstr\u00f6m","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201103000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:28Z","timestamp":1786369108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201103000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09091010","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}